Emerging Pathogens, Vaccine and Breakthrough Infection News and Medical Cases
No significant difference in hospitalization between immunized and non-immunized found for SARS-CoV-2 Beta variant
Get link
Facebook
X
Pinterest
Email
Other Apps
A study of vaccinated and unvaccinated residents of Bangladesh observed that ChAdOx1 could not prevent the new infection or severe COVID-19 disease outcome with single dose when infections were mostly caused by B.1.351 (the Beta) variants of SARS-CoV2.
About 39% (n = 42) of the respondents were infected after the COVID-19 vaccination. The first dose of ChAdOx1 nCoV-19 vaccine was received by 40 (37.0%) cases and both doses were completed by only 2 (2%) cases. The average duration between vaccination (partially or completely immunized) and COVID 19 diagnosis was 32 (±17) days.
The hospitalization rate of comorbid patients was 23.5% among the immunized and 24.1% among the nonimmunized groups. There was no significant difference in duration of hospitalization either (p=0.78).
Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh
Al-Emran HM, Hasan MS, Setu MA, Rahman MS, Alam AR, Sarkar SL, Islam MT, Islam MR, Rahman MM, Islam OK, Jahid IK. Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. Journal of Infection and Public Health. 2021 Dec 7.
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine. Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes. There are ten published case reports about the newly diagnosed ulcerative colitis ...
Previously we presented case reports with oral side effects of COVID-19 vaccine due to mucocutaneous reactions. Trigeminal neuralgia (TN) could be another reason for oral manifestations, including severe tooth pain. A 45-year-old female was admitted to a research hospital with 3 days of facial and jaw pain, fatigue and toothache following the first dose of Pfizer-BioNtech vaccine against SARS-CoV-2. The features of the pain were unilateral, acute onset, and severe, on the lower right side of the face. It was triggering with brushing her teeth and putting on makeup. The case was considered as trigeminal neuralgia. Pregabalin failed to control the pain, while amoxicillin/clavulanic acid (despite normal X-rays) led to angioedema and worsening of her general condition. However, with steroid treatment, the patient eventually recovered. A 36-year-old woman was admitted to the Emergency Ward due to chronic pain attacks in the left side of her face. The pain appeared tw...
Post-Vaccination IgG4 and IgG2 Class Switching is linked to Increased Risk of SARS-CoV-2 Infections A new study published in Infectious Disease Practice has revealed a concerning correlation between the class switching of antibodies after COVID-19 mRNA booster vaccinations and a heightened risk of breakthrough infections. Specifically, the study found that elevated levels of IgG4 and IgG2 antibodies, which increase significantly following the third mRNA dose, are linked to an increased risk of symptomatic SARS-CoV-2 infections. The study followed a longitudinal cohort of 83 healthcare workers who received three vaccine doses, with an additional 66 participants analyzed at a specific timepoint (T9, May 2022), four months after the first booster. Conducted in Spain, the research tracked immune responses over nearly three years, revealing that the proportion of non-cytophilic antibodies (IgG4 and IgG2) increased relative to cytophilic subclasses (IgG1 and IgG3) after the booster. Th...
Comments
Post a Comment